I. MODIFIED AGREEMENTS

Chrysalin BioTechnology Inc.*

OrthoLogic Corp. (OLGC)

Expansion of 1/99 agreement covering fracture healing indications for Chrysalin (synthetic 23-amino-acid peptide) in the U.S. (7/00)

$2

OrthoLogic will pay Chrysalin a one-time fee of $2M, plus milestones and possible royalties to expand license to include all orthopedic indications and extend agreement worldwide

Emisphere Technologies Inc. (EMIS)

Eli Lilly and Co. (NYSE:LLY)

Expansion of 2/97 development and research collaboration for oral formulations of Forteo and Humatrop utilizing Emisphere's proprietary drug delivery technology

$2

The new agreement provides for supplemental research and development funding; Emisphere will immediately receive a $2M milestone payment under the terms in the previous agreement (6/00)

Exelixis Inc. (EXEL)

Bristol-Myers Squibb Co. (NYSE:BMY)

Expansion of 9/99 technology access and research agreement under which Exelixis identifies the mechanism of action for pharmaceutical compounds received from Bristol-Myers

ND

Bristol-Myers will double its committed research funding for the remainder of the agreement (6/00)

Icos Corp. (ICOS)

Abbott Laboratories (NYSE:ABT)

Change in 1995 agreement covering LFA-1 antagonists for inflammation

ND

Icos acquired marketing rights for all compounds in all indications worldwide; Abbott will receive royalties on any marketed products (6/00)

Incyte Genomics Inc. (INCY)

Aventis Research & Technologies GmbH & Co. KG (NYSE:AVE)

Expansion of collaboration; Incyte has had agreements with Rhone Poulenc SA and Hoechst AG (since merged to form Aventis)

ND

Incyte expanded its agreement with Aventis to include access to to Incyte's custom SNP program and will focus on identifying individual single nucleotide polymorphisms that affect drug matabolism (6/00)

Incyte Genomics Inc. (INCY)

Eli Lilly and Co. (NYSE:LLY)

Expansion of 12/96 database subscription agreement; companies will collaborate on the development of therapeutic proteins

ND

Eli Lilly will obtain options to license multiple therapeutic protein patents from Incyte (6/00)

Karo Bio AB-(Sweden; SSE:KARO)

Bristol-Myers Squibb Co. (NYSE:BMY)

Extension of 10/97 development agreement focused on the development of substances acting selectively on thyroid hormone receptor as a way to regulate dysmetabolic syndromes while sparing cardiovascular side effects

ND

The two companies have created first-generation drugs and will now focus on developing second-generation lead compounds (7/00)

NaPro Bio Therapeutics Inc. (NPRO)

F.H. Faulding & Co. Ltd.* (Australia)

Expansion of 1/95 development and marketing collaboration for NaPro's paclitaxel

ND

Companies expanded agreement to provide Faulding exclusive rights in all of Central America, South America, Mexico, South Africa and certain additional territories in Southeast Asia and the Middle East (6/00)

Oxford BioMedica (UK; LSE:OXB)

Aventis Pharmaceuticals Inc. (NYSE:AVE)

Extension of 12/98 collaboration that gave Aventis rights to use BioMedica's Hypoxia Response Element (HRE) in gene therapy for cardiovascular disease

ND

Under the new agreement, Aventis will have access to BioMedica's proprietary LentiVector gene delivery vectors in cardiovascular gene therapy product research and development programs (6/00)

OSI Pharmaceuticals Inc. (OSIP)

Pfizer Inc. (NYSE:PFE)

New licensing agreement for Phase II anticancer compound, CP-358,774 (OSI-774), that emerged from collaboration begun

ND

OSI gains all development and marketing rights to CP-358,774 (OSI-774); OSI will receive royalty-free license to all rights for the further development and commercialization of the product; Pfizer had to license the compound to OSI because Warner-Lambert Co., which Pfizer acquired, was developing a similar product (7/00)

SkyePharma plc (UK; SKYE)

Pfizer Inc. (NYSE:PFE)

Addition to development agreement of 3/00 with Pfizer; SkyePharma is using its proprietary DepoFoam sustained-release injection technology to formulate a Pfizer compound

ND

ND (5/00)

Xoma Ltd. (XOMA)

Allergan (NYSE:AGN)

Expansion of 6/99 development collaboration for ophthalmic anti-infective product that combines rBPI (recombinant bactericidal permeability-increasing protein) with antibiotics to treat bacterial eye infections

ND

The amended agreement provides for additional milestone payments; Allergan will continue to pay all future development costs and Xoma will be entitled to royalties on net sales worldwide on all Allergan anti-infective products that incorporate rBPI; a Xoma affiliate will manufacture rBPI for Allergan (5/00)

II. TERMINATED AGREEMENTS

Alkermes Inc. (ALKS)

Johnson & Johnson (NYSE:JNJ)

J&J terminated 1/98 collaboration to develop sustained-release formulation of erythro-poietin using Alkermes' ProLease technology

ND

Original agreement was worth more than $30M; no reason was given for the project's demise (6/00)

NOTES

# The information in the chart does not cover agreements between biotech companies or agricultural agreements.

* Private companies are indicated with an asterisk; unless otherwise noted, stock symbols listed are on the NASDAQ market.

ND = Not disclosed, reported and/or available

AMEX = American Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over The Counter Bulletin Board.

No Comments